was about 44 times as high as that of diaphragm's. Subsequently, the effect of 10275-S (1mg/ mouse) pretreatment on the uptake of tritiated estradiol were measured 4hr after the injection of estradiol-6,7-3H2. Results are presented in Figure 2 . Pretreatment with 10275-S either 4 or 24hr before tritiated estradiol administration caused significant decrease (P<0.05) in uterine radioactivity by approximate 60 and 30% of the control, respectively. The concentration of radioactivity in vagina also decreased significantly (P<0.05) to 60% of the control when 10275-S was given 24hr prior to the tritiated estrogen, but did not significantly decrease when given 4hr earlier. Moderate accumulation of radioactivity was also noted in the pituitary, but no significant effect of 10275-S was observed.
The effect of 10275-S on uterine estradiol uptake was compared with those of testosterone and progesterone by giving 1mg of these steroids 24hr before tritiated estradiol injection. As shown in Figure 3 , 10275-S, testosterone and progesterone significantly (P<0.05) reduced the concentration of uterine radioactivity to 30, 56 and 71% of the control, respectively. However, these treatments increased uterine weight about 1.8-,
1.7-and 1.3-fold over the control, respectively.
As a result, total uterine radioactivity was not altered by the pretreatment of testosterone or progesterone, whereas 1mg of 10275-S sig-ni ficantly (P < 0.05) inhibited the accumulation of radioactivity in the whole uterus to 55% of the control.
3. Effect of 10275-S on estradiol binding by rat uterine cytosol Figure 4 presents a typical distribution pattern of radioactivity after sucrose gradient centrifugation of the uterine cytosol incubated unesterified at the 17-hydroxy group. This may correlate with the fact that subcutaneously given 10275-S showed a high affinity with uterus and vagina, and prolonged distribution in these tissues (Hori et al., 1970) . It has been generally accepted that the initial response of estrogen sensitive tissue to estradiol is an accumulation of estrogen by the specific binding to macromolecular receptor of the cells (Jensen et al., 1968 and Gorski et al., 1969) . A variety of non-steroidal anti-estrogens, especially amino-ether derivatives of polycyclic phenols have been known to act by competing with specific estrogen binding sites of the target tissue (Jensen et al., 1966; Wyss et al., 1968; Korenman, 1969b; Terenius, 1970; Rochefort and Capony, 1971; Skidmore et al., 1972 
